Vážení uživatelé, vítáme Vás v nové podobě uživatelského rozhraní Repozitáře publikační činnosti UK. Budeme rádi, když nám věnujete chvíli Vašeho času a poskytnete nám k nové podobě repozitáře zpětnou vazbu.
Dear users, welcome to the new interface of the Charles University Publication Repository. We would appreciate it if you could take a moment of your time to provide us with feedback on the new design of the repository.
Dotazník pro zpětnou vazbu je dostupný na URL adrese / The feedback questionnaire is available at the URL address: https://forms.office.com/e/ueBL8SYPZt
Dear users, welcome to the new interface of the Charles University Publication Repository. We would appreciate it if you could take a moment of your time to provide us with feedback on the new design of the repository.
Dotazník pro zpětnou vazbu je dostupný na URL adrese / The feedback questionnaire is available at the URL address: https://forms.office.com/e/ueBL8SYPZt
Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms
dc.contributor.author | Bitar, Ibrahim | |
dc.contributor.author | Salloum, Tamara | |
dc.contributor.author | Merhi, Georgi | |
dc.contributor.author | Hrabák, Jaroslav | |
dc.contributor.author | Araj, George F. | |
dc.contributor.author | Tokajian, Sima | |
dc.date.issued | 2022 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/1788 | |
dc.description.abstract | Resistance to ceftolozane/tazobactam (C/T) in Pseudomonas aeruginosa is a health concern. In this study, we conducted a whole-genome-based molecular characterization to correlate resistance patterns and β-lactamases with C/T resistance among multi-drug resistant P. aeruginosa clinical isolates. Resistance profiles for 25 P. aeruginosa clinical isolates were examined using disk diffusion assay. Minimal inhibitory concentrations (MIC) for C/T were determined by broth microdilution. Whole-genome sequencing was used to check for antimicrobial resistance determinants and reveal their genetic context. The clonal relatedness was evaluated using MLST, PFGE, and serotyping. All the isolates were resistant to C/T. At least two β-lactamases were detected in each with the blaOXA-4, blaOXA-10, blaOXA-50, and blaOXA-395 being the most common. blaIMP-15, blaNDM-1, or blaVIM-2, metallo-β-lactamases, were associated with C/T MIC >256 μg/mL. Eight AmpC variants were identified, and PDC-3 was the most common. We also determined the clonal relatedness of the isolates and showed that they grouped into 11 sequence types (STs) some corresponding to widespread clonal complexes (ST111, ST233, and ST357). C/T resistance was likely driven by the acquired OXA β-lactamases such as OXA-10, and OXA-50, ESBLs GES-1, GES-15, and VEB-1, and metallo- β-lactamases IMP-15, NDM-1, and VIM-2. Collectively, our results revealed C/T resistance determinants and patterns in multi-drug resistant P. aeruginosa clinical isolates. Surveillance programs should be implemented and maintained to better track and define resistance mechanisms and how they accumulate and interact. | en |
dc.language.iso | en | |
dc.relation.url | https://doi.org/10.3389/fcimb.2022.922976 | |
dc.rights | Creative Commons Uveďte původ 4.0 International | cs |
dc.rights | Creative Commons Attribution 4.0 International | en |
dc.title | Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms | en |
dcterms.accessRights | restrictedAccess | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/legalcode | |
dc.date.updated | 2023-10-02T06:15:30Z | |
dc.subject.keyword | AmpC | en |
dc.subject.keyword | beta lactamases | en |
dc.subject.keyword | ceftolozane/tazobactam (C/T) | en |
dc.subject.keyword | porins | en |
dc.subject.keyword | Pseudomonas aeruginosa | en |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/I-UK/I-LFP | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU20J-05-00033 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM/EF/EF16_019/0000787 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/PROGRES/Q39 | |
dc.date.embargoStartDate | 2023-10-02 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.3389/fcimb.2022.922976 | |
dc.identifier.utWos | 000818484000001 | |
dc.identifier.eidScopus | 2-s2.0-85133220193 | |
dc.identifier.obd | 612728 | |
dc.identifier.riv | RIV/00216208:11140/22:10445070 | |
dc.identifier.pubmed | 35782142 | |
dc.subject.rivPrimary | 30000::30300::30303 | |
dc.relation.datasetUrl | https://www.frontiersin.org/articles/10.3389/fcimb.2022.922976/full#supplementary-material | |
dcterms.isPartOf.name | Frontiers in Cellular and Infection Microbiology | |
dcterms.isPartOf.issn | 2235-2988 | |
dcterms.isPartOf.journalYear | 2022 | |
dcterms.isPartOf.journalVolume | 12 | |
dcterms.isPartOf.journalIssue | June | |
uk.faculty.primaryId | 111 | |
uk.faculty.primaryName | Lékařská fakulta v Plzni | cs |
uk.faculty.primaryName | Faculty of Medicine in Pilsen | en |
uk.faculty.secondaryId | 54 | |
uk.faculty.secondaryName | Fakultní nemocnice Plzeň | cs |
uk.faculty.secondaryName | University Hospital in Pilsen | en |
uk.department.primaryId | 100012968318 | |
uk.department.primaryName | Biomedicínské centrum | cs |
uk.department.primaryName | Biomedical Center | en |
uk.department.secondaryId | 5000002737 | |
uk.department.secondaryId | 1359 | |
uk.department.secondaryName | Ústav mikrobiologie | cs |
uk.department.secondaryName | Ústav mikrobiologie | en |
uk.department.secondaryName | Ústav mikrobiologie | cs |
uk.department.secondaryName | Department of Microbiology | en |
dc.description.pageRange | nestránkováno | |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::původní článek | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::original article | en |
dc.type.obdHierarchyCode | 73::152::206 | en |
uk.displayTitle | Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms | en |